Plasmablastic lymphomas show restricted EBV latency profile and MYC gene aberrations

References

• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: IARC; 2017.
   Google Scholar
• Tchernonog E, Faurie P, Coppo P, et al. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. Ann Oncol. 2017;28(4):843–848.
   PubMed Web of Science ®Google Scholar
• Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89(4):1413–1420.
   PubMed Web of Science ®Google Scholar
• Castillo J, Pantanowitz L, Dezube B. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol. 2008;83(10):804–809.
   PubMed Web of Science ®Google Scholar
• Boy S, van Heerden M, Babb C, et al. Dominant genetic aberrations and coexistent EBV infection in HIV-related oral plasmablastic lymphomas. Oral Oncol. 2011;47(9):883–887.
   PubMed Web of Science ®Google Scholar
• Pather S, Mashele T, Willem P, et al. MYC status in HIV-associated plasmablastic lymphoma: dual-colour CISH, FISH and immunohistochemistry. Histopathology. 2021;79(1):86–95.
   PubMed Web of Science ®Google Scholar
• Lopez A, Abrisqueta P. Plasmablastic lymphoma: current perspectives. Blood Lymphat Cancer. 2018;8:63–70.
   PubMed Web of Science ®Google Scholar
• Price A, Luftig M. To be or not IIb: a multi-step process for Epstein-Barr virus latency establishment and consequences for B cell tumorigenesis. PLoS Pathog. 2015;11(3):e1004656.
   PubMed Web of Science ®Google Scholar
• Di Pietro A. Epstein-Barr virus promotes B cell lymphomas by manipulating the host epigenetic machinery. Cancers. 2020;12(10):3037.
   Web of Science ®Google Scholar
• Weed DJ, Damania B. Pathogenesis of human gammaherpesviruses: recent advances. Curr Clin Microbiol Rep. 2019;6(3):166–174.
   PubMed Web of Science ®Google Scholar
• Miao L, Guo N, Feng Y, et al. High incidence of MYC rearrangement in human immunodeficiency virus-positive plasmablastic lymphoma. Histopathology. 2020;76(2):201–211.
   PubMed Web of Science ®Google Scholar
• Liu Z, Filip I, Gomez K, et al. Genomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK–STAT pathway. Blood Cancer Discov. 2020;1(1):112–125.
   PubMedGoogle Scholar
• Ramis-Zaldivar JE, Gonzalez-Farre B, Nicolae A, et al. MAP-kinase and JAK-STAT pathways dysregulation in plasmablastic lymphoma. Haematologica. 2021;6–54.
   Google Scholar
• Garcia-Reyero J, Martinez-Magunacelaya N, Gonzalez de Villambrosia S, et al. Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma. Haematologica. 2021;106(4):1120–1128.
   PubMed Web of Science ®Google Scholar
• Valera A, Balague O, Colomo L, et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol. 2010;34(11):1686–1694.
   PubMed Web of Science ®Google Scholar
• Hubel K. The changing landscape of lymphoma associated with HIV infection. Curr Oncol Rep. 2020;22(11):111.
   PubMed Web of Science ®Google Scholar
• Bibas M, Castillo J. Current knowledge on HIV-associated plasmablastic lymphoma. Mediterr J Hematol Infect Dis. 2014;6(1):e2014064.
   PubMedGoogle Scholar
• Nguyen L, Papenhausen P, Shao H. The role of c-MYC in B-cell lymphomas: diagnostic and molecular aspects. Genes. 2017;8(4):116.
   PubMed Web of Science ®Google Scholar
• Liu F, Asano N, Tatematsu A, et al. Plasmablastic lymphoma of the elderly: a clinicopathological comparison with age-related Epstein-Barr virus-associated B cell lymphoproliferative disorder. Histopathology. 2012;61(6):1183–1197.
   PubMed Web of Science ®Google Scholar
• Morscio J, Dierickx D, Nijs J, et al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients. Am J Surg Pathol. 2014;38(7):875–886.
   PubMed Web of Science ®Google Scholar
• Ambrosio M, Mundo L, Gazaneo S, et al. MicroRNAs sequencing unveils distinct molecular subgroups of plasmablastic lymphoma. Oncotarget. 2017;8(64):107356–107373.
   PubMedGoogle Scholar
• Jha H, Pei Y, Robertson E. Epstein-Barr virus: disease linked to infection and transformation. Front Microbiol. 2016;7:1602.
   PubMed Web of Science ®Google Scholar
• Kelly GL, Milner AE, Baldwin GS, et al. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc Natl Acad Sci U S A. 2006;103(40):14935–14940.
   PubMed Web of Science ®Google Scholar
• Skalsky RL, Cullen BR. EBV noncoding RNAs. Curr Top Microbiol Immunol. 2015;391:181–217.
   PubMed Web of Science ®Google Scholar
• Bullard WL, Flemington EK, Renne R, et al. Connivance, complicity, or collusion? The role of noncoding RNAs in promoting gammaherpesvirus tumorigenesis. Trends Cancer. 2018;4(11):729–740.
   PubMed Web of Science ®Google Scholar
• Wilson JB, Manet E, Gruffat H, et al. EBNA1: oncogenic activity, immune evasion and biochemical functions provide targets for novel therapeutic strategies against Epstein-Barr virus-associated cancers. Cancers. 2018;10(4):109.
   Web of Science ®Google Scholar
• Jiang L, Xie C, Lung HL, et al. EBNA1-targeted inhibitors: novel approaches for the treatment of Epstein-Barr virus-associated cancers. Theranostics. 2018;8(19):5307–5319.
   PubMed Web of Science ®Google Scholar
• Linke-Serinsöz E, Fend F, Quintanilla-Martinez L. Human immunodeficiency virus (HIV) and Epstein-Barr virus (EBV) related lymphomas, pathology view point. Semin Diagn Pathol. 2017;34(4):352–363.
   PubMed Web of Science ®Google Scholar
• Zhang B, Kracker S, Yasuda T, et al. Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model. Cell. 2012;148(4):739–751.
   PubMed Web of Science ®Google Scholar
• Castillo J, Bibas M, Miranda R. The biology and treatment of plasmablastic lymphoma. Blood. 2015;125(15):2323–2330.
   PubMed Web of Science ®Google Scholar
• Vecchio E, Fiume G, Correnti S, et al. Insights about MYC and apoptosis in B-lymphomagenesis: an update from murine models. Int J Mol Sci. 2020;21(12):4265.
   Web of Science ®Google Scholar
• Loghavi S, Alayed K, Aladily TN, et al. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients. J Hematol Oncol. 2015;8(1):65.
   PubMedGoogle Scholar
• Montes-Moreno S, Martinez-Magunacelaya N, Zecchini-Barrese T, et al. Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1. Mod Pathol. 2017;30(1):85–94.
   PubMed Web of Science ®Google Scholar
• Laurent C, Fabiani B, Do C, et al. Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients. Haematologica. 2016;101(8):976–984.
   PubMed Web of Science ®Google Scholar
• Castillo J, Furman M, Beltrán Brady E, et al. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer. 2012;118(21):5270–5277.
   PubMed Web of Science ®Google Scholar